|
Name |
1H-Cycloundec(d)isoindole-1,12,15-trione, 2,3,3a,4,6a,9,10,11-octahydro-11-hydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-, (3S,3aR,4S,6aS,7E,11S,13E,15aS)-
|
Molecular Formula | C24H33NO4 | |
IUPAC Name* |
(1S,3Z,6S,9Z,11S,14S,15R,16S)-6-hydroxy-9,13,14-trimethyl-16-(2-methylpropyl)-17-azatricyclo[9.7.0.01,15]octadeca-3,9,12-triene-2,5,18-trione
|
|
SMILES |
C[C@H]1[C@H]2[C@@H](NC(=O)[C@@]23[C@@H](/C=C(\CC[C@@H](C(=O)/C=C\C3=O)O)/C)C=C1C)CC(C)C
|
|
InChI |
InChI=1S/C24H33NO4/c1-13(2)10-18-22-16(5)15(4)12-17-11-14(3)6-7-19(26)20(27)8-9-21(28)24(17,22)23(29)25-18/h8-9,11-13,16-19,22,26H,6-7,10H2,1-5H3,(H,25,29)/b9-8-,14-11-/t16-,17+,18+,19+,22+,24-/m1/s1
|
|
InChIKey |
BVKOTAZOMFVYMH-YBCLPTENSA-N
|
|
Synonyms |
72363-47-4; Aspochalasin B; 1H-Cycloundec(d)isoindole-1,12,15-trione, 2,3,3a,4,6a,9,10,11-octahydro-11-hydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-, (3S,3aR,4S,6aS,7E,11S,13E,15aS)-
|
|
CAS | 72363-47-4 | |
PubChem CID | 6440467 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 399.5 | ALogp: | 2.8 |
HBD: | 2 | HBA: | 4 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 83.5 | Aromatic Rings: | 3 |
Heavy Atoms: | 29 | QED Weighted: | 0.544 |
Caco-2 Permeability: | -4.855 | MDCK Permeability: | 0.00002610 |
Pgp-inhibitor: | 0.999 | Pgp-substrate: | 0.035 |
Human Intestinal Absorption (HIA): | 0.012 | 20% Bioavailability (F20%): | 0.765 |
30% Bioavailability (F30%): | 0.807 |
Blood-Brain-Barrier Penetration (BBB): | 0.95 | Plasma Protein Binding (PPB): | 86.49% |
Volume Distribution (VD): | 0.434 | Fu: | 13.19% |
CYP1A2-inhibitor: | 0.016 | CYP1A2-substrate: | 0.126 |
CYP2C19-inhibitor: | 0.236 | CYP2C19-substrate: | 0.871 |
CYP2C9-inhibitor: | 0.207 | CYP2C9-substrate: | 0.12 |
CYP2D6-inhibitor: | 0.009 | CYP2D6-substrate: | 0.064 |
CYP3A4-inhibitor: | 0.77 | CYP3A4-substrate: | 0.678 |
Clearance (CL): | 12.477 | Half-life (T1/2): | 0.793 |
hERG Blockers: | 0.037 | Human Hepatotoxicity (H-HT): | 0.1 |
Drug-inuced Liver Injury (DILI): | 0.077 | AMES Toxicity: | 0.155 |
Rat Oral Acute Toxicity: | 0.13 | Maximum Recommended Daily Dose: | 0.876 |
Skin Sensitization: | 0.89 | Carcinogencity: | 0.799 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.011 |
Respiratory Toxicity: | 0.932 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004242 | 0.753 | D0D2TN | 0.238 | ||||
ENC002636 | 0.733 | D05AFC | 0.237 | ||||
ENC004462 | 0.714 | D0K7LU | 0.233 | ||||
ENC003740 | 0.695 | D06YFA | 0.231 | ||||
ENC005810 | 0.639 | D0P1FO | 0.224 | ||||
ENC005136 | 0.622 | D09WYX | 0.221 | ||||
ENC005825 | 0.548 | D0I5DS | 0.218 | ||||
ENC002049 | 0.528 | D09PJX | 0.214 | ||||
ENC003433 | 0.480 | D0E9KA | 0.212 | ||||
ENC005809 | 0.438 | D0W2EK | 0.211 |